Locations

Studies

Join a study.
Help find a cure.

Every medical breakthrough we celebrate and benefit from is because of volunteers just like you. Everyday people who say “yes” to participating in clinical trials are changing the world for the better.

Explore our open studies — each one represents an opportunity to help build healthier futures.

Select a condition
to view the relevant open studies

Additional Filters

Alzheimer’s Agitation Study

Agitation in all its forms—from finger tapping, nail biting and restlessness to excessive motor activity, verbal aggression, and physical aggression—is particularly challenging because there are currently no effective treatments for it.

Preliminary Qualifications

  • 55+ years of age.
  • Confirmed high likelihood of Alzheimer's disease, using either a blood-based biomarker or cerebrospinal fluid biomarker.
  • Exhibit one of more of the following: excessive motor activity, verbal aggression, physical aggression.
  • Agitation is not solely attributable to another psychiatric, medical, or environmental condition.
Get involved

Alzheimer’s Tau Protein Study

The next generation of drugs in the battle against Alzheimer’s disease may possibly be tau protein-targeting antibodies. Tau proteins normally contribute to the health of neurons in the brain, but are damaged by Alzheimer’s disease.

Preliminary Qualifications

  • You are 50-90 years old.
  • You have a clinical diagnosis of early-Alzheimer's.
  • Or you have evidence of pathology consistent with Alzheimer's disease.
Get involved

Alzheimer’s Biomarker Study

Imagine your body is like a car, and you want to know how it's running. A biomarker is like a gauge or a warning light on the dashboard, something measurable that may indicate if you have a disease, how well a treatment is working, or if you're at risk for a future health problem.

Preliminary Qualifications

  • You are between 60-90 years old.
  • You have a close study partner.
Get involved

Alzheimer’s Cortisol Study

The investigational drug was developed in response to evidence of a strong association between chronically-raised cortisol levels and the development of cognitive impairment in Alzheimer’s disease. The drug is designed to target and block production of cortisol inside brain neurons.

Preliminary Qualifications

  • You are at least 50 years old.
  • You have mild or moderate dementia, likely to be due to Alzheimers, in the opinion of the Principal Investigator.
  • You have a reliable study partner.
Get involved

Alzheimer’s Neurotransmitter Study

Patients with mild to moderate Alzheimer’s disease often have negative changes in how efficiently their bodies process dopamine, a neurotransmitter that helps nerve cells send messages to each other. This can lead to adverse changes in personality, mood, and behavior. This investigational drug enhances the body’s ability to utilize dopamine.

Preliminary Qualifications

  • You are 50-80 years old
  • You have gradual & progressive decline in memory function for more than 6 months.
  • You have historical evidence of Alzheimer's disease
Get involved

Obesity & Diabetes Trial

While weight management strategies exist, finding long-term solutions and understanding the root causes of obesity remain ongoing challenges. If you’re worried that you can’t manage your weight now or in the future, then joining an obesity study might be a great option for you. It might just help future generations, too.

Preliminary Qualifications

  • Clinical diagnosis of Type 2 diabetes
  • BMI > 30 or
  • BMI > 27 with hypertension, dyslipidemia, cardiovascular disease, or obstructive sleep apnea
Get involved

Lung Research Studies

We’re validating a blood test to screen for lung cancer. We hope this innovative new test may one day indicate if you need further evaluation. Early detection matters. Detecting cancer early can improve treatment outcomes and survival. The 5-year survival rate for lung cancer is 8x higher if found before it spreads!  

Preliminary Qualifications

  • Current or former smoker
  • Age 50 years or older
  • Have scheduled or are willing to schedule a low-dose CT scan
Get involved

Early Alzheimer’s Study

The purpose of this early-Alzheimer's study is to find out if the study drug can possibly prevent, delay, or slow early symptoms of Alzheimer’s disease. It is thought this new investigational drug may help the blood vessels in your brain work better by increasing blood flow to the brain, reducing inflammation, and possibly curtailing amyloid protein production, a major biomarker for Alzheimer's.

Preliminary Qualifications

  • 50-90 years of age.
  • You have mild cognitive impairment or mild dementia consistent with Alzheimer's disease, but can complete most daily tasks independently.
  • Ability to swallow capsules or pills.
Get involved

MASH Study

This study is for people with a diagnosis of metabolic dysfunction-associated steatohepatitis (MASH), which is a condition that causes liver inflammation and damage due to a buildup of fat in the liver. The investigational drug is being developed as a possible treatment for MASH.

Preliminary Qualifications

  • 18-75 years of age.
  • Diagnosis of MASH (metabolic dysfunction-associated steatohepatitis)
  • BMI greater than or equal to 27.
Schedule Your Assessment

Obesity Study

Obesity is a complex disease with many underlying causes and impacts on health. This study is to test a new drug with the potential to deliver substantial body weight reduction across the spectrum of obesity.

Preliminary Qualifications

  • You are at least 18 years of age.
  • You have a BMI greater than 35.
  • You have—or have experienced—one or more of the following: type 2 diabetes, heart attack, stroke, or peripheral arterial disease
Get involved

Alzheimer’s End-Of-Life Study

The purpose of this end-of-life study is to evaluate the effectiveness of a new brain (PET) scan in accurately detecting Alzheimer’s disease. We hope that earlier, more accurate detection of Alzheimer’s disease will one day allow patients to confirm their diagnosis more easily, and then they can confidently begin new treatments that may delay—or eventually even reverse—the progression of the disease.

Preliminary Qualifications

  • You are 50+ years of age.
  • You have a projected life expectancy of less than or equal to 1 year.
  • You can lay down for a brain scan (PET scan).
Get involved

Schedule Your Assessment

Sign up for an initial assessment (called a “prescreen”), and we'll give you a call. One of our professional medical staff will answer your questions and give you more information about Charter Research prior to an in-office visit.

Get More Information

Your contact information

Newsletter
Consent
This field is for validation purposes and should be left unchanged.